VIVUS Inc. (VVUS)

4.29
NASDAQ : Health Technology
Prev Close 4.17
Day Low/High 4.14 / 4.31
52 Wk Low/High 2.15 / 5.78
Avg Volume 115.60K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 44.38M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Arena: FDA Adds Obesity Docs to Panel

Arena: FDA Adds Obesity Docs to Panel

Getting ready for the May 10 FDA advisory panel reviewing Arena's obesity drug lorcaserin.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Arena Pharma's Own Data Point to Weight-Loss Drug Rejection

Arena Pharma's Own Data Point to Weight-Loss Drug Rejection

More reasons to doubt Arena's ability to convince FDA to approve its obesity drug lorcaserin.

'Mad Money' Lightning Round: Broadcom In, Vivus Out

'Mad Money' Lightning Round: Broadcom In, Vivus Out

In the Lightning Round, Cramer was bullish on MON, HEK, BRCM and OC, bearish on VVUS and a few others.

Stocks Fall for Fifth Straight Session

Stocks Fall for Fifth Straight Session

The Dow loses more than 200 points in a broad sell-off ahead of earnings season as eurozone worries return with a vengeance.

Vivus Obesity Drug Delay Is Good and Still Means Arena Pharma Rejection

Vivus Obesity Drug Delay Is Good and Still Means Arena Pharma Rejection

The latest twists and turns in the race for FDA approval of a new weight-loss drug.

Top FDA Approval Decision Gurus Weigh In on Vivus' Obesity Drug

Top FDA Approval Decision Gurus Weigh In on Vivus' Obesity Drug

Hear what the top contestants in TheStreet's FDA Drug Approval Contest have to say about Vivus and its obesity drug.

Stocks to Watch: Alcoa, Sony

Stocks to Watch: Alcoa, Sony

Alcoa kicks off earnings season Tuesday; analysts expect the aluminum maker to post a loss of 4 cents a share.

Market Preview: Hitting Pause

Market Preview: Hitting Pause

The selling in stocks is starting to add up but the jury is still out on whether the long-awaited pullback has finally arrived.

Harmonic, VIVUS: After-Hours Trading

Harmonic, VIVUS: After-Hours Trading

These stocks drew trading interest in Monday's extended session.

The Red Sea

Other than a few gold miners and some odds and ends, there is almost no green out there. 

Biotech Stock Mailbag: Ampio, Cel-Sci and Ziopharm

Biotech Stock Mailbag: Ampio, Cel-Sci and Ziopharm

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

The Next Big Thing in Biotech: Vivus

The Next Big Thing in Biotech: Vivus

Senior columnist Adam Feuerstein explains why Vivus is the next big thing in biotech.

Wednesday's Top 10 Articles, Videos on TheStreet

Wednesday's Top 10 Articles, Videos on TheStreet

These stories made today's top 10 list of articles and videos on TheStreet.

For Biotech Takeovers, Timing is Key

For Biotech Takeovers, Timing is Key

Speculation swirls about a Vivus takeover, but history says an imminent deal isn't likely.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

No Quit in This Market

With the words 'quantitative easing' in the air, who knows how much higher the market can go.

Return of the Dip-Buyers

It's the closest you can get to a sure thing in this market.

Dip Disinterest

The selling seems to be more about the dip-buyers losing interest than rushing for the exits.

Follow the Hot Money

It's easier to find the hot action in a slow market because it's more concentrated.

Staying Prepared

I'm refining my buy list and prioritizing the names I'm pursuing as charts develop.

Biotech Stock Chat: Recap

Biotech Stock Chat: Recap

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech and biotech stock investing.

It's Tradin' Time

I'm not going to waste time timing the market. There's money to be made trading individual stocks.

Ready to Squeeze Shorts

The week's worst performers have bounced at support and look ready to move higher, specifically raw materials and agricultural stocks.

Friday's Top 10 Articles, Videos on TheStreet

Friday's Top 10 Articles, Videos on TheStreet

These stories made today's top 10 list of articles and videos on TheStreet.

Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash

Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More

More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More

Biotech columnist Adam Feuerstein responds to biotech stock questions posed by his Twitter followers.

'Mad Money Lightning Round': Go for Check Point Software

'Mad Money Lightning Round': Go for Check Point Software

Cramer says the company has good momentum

8 Stocks Rising on Unusual Volume

8 Stocks Rising on Unusual Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Analysts' Actions: HP, VVUS, JNPR, K

Analysts' Actions: HP, VVUS, JNPR, K

Here are today's top research calls.

TheStreet Quant Rating: D (Sell)